Abstract
Arboviruses such as flaviviruses and alphaviruses cause a significant human healthcare burden on the global scale. Transmission of these viruses occurs during human blood feeding at the mosquito-skin interface. Not only do pathogen immune evasion strategies influence the initial infection and replication of pathogens delivered, but arthropod salivary factors also influence transmission foci. In-vitro cell cultures do not provide an adequate environment to study complex interactions between viral, mosquito, and host factors. To address this need for a whole tissue system, we describe a proof-of-concept model for arbovirus infection using adult human skin ex vivo with Zika virus (flavivirus) and Mayaro virus (alphavirus). Replication of these viruses in human skin was observed up to 4 days post-infection. Egressed viruses could be detected in the culture media as well. Antiviral and pro-inflammatory genes, including chemoattractant chemokines, were expressed in infected tissue. Immunohistochemical analysis showed the presence of virus in the skin tissue at 4 days post-infection. This model will be useful to further investigate: 1) the immediate molecular mechanisms of arbovirus infection in human skin, and 2) the influence of arthropod salivary molecules during initial infection of arboviruses in a more physiologically relevant system.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: The study described in this manuscript was funded by Departmental Start-up funds and SUNY Empire Innovation Professorship funds to ST
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All experiments involving de-identified human specimens were conducted in a biological safety level 2 (BSL-2) laboratory in accordance with a protocol approved by the SUNY Upstate Medical University Institutional Review Board (IRB).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations used
- (ZIKV)
- Zika virus
- (MAYV)
- Mayaro virus
- (CHIKV)
- Chikungunya virus
- (SPOV)
- Spondweni virus
- (USUV)
- Usutu virus
- (BSL-2)
- biological safety level 2
- (IRB)
- Institutional Review Board
- (HI-FBS)
- heat-inactivated fetal bovine serum
- (qRT-PCR)
- quantitative reverse transcriptase PCR
- (LAS-X)
- Leica Application Suite X
- (MOI)
- multiplicity of infection
- (PRR)
- pattern recognition receptor
- (IFITMs)
- Interferon-induced transmembrane proteins
- (SEM)
- standard error of the mean
